Novartis AG vs SiTime Corporation — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while SiTime Corporation trades at $654.38 (market cap $19.99B). The key difference: Novartis AG is far larger — about 13.7× SiTime Corporation's market cap, and Novartis AG pays a 3.31% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and SiTime Corporation for 18 Days on average.
| NVS | SITM | |
|---|---|---|
Market Cap | $274.00B | $19.99B |
Volume | 1,852,137 | 339,821 |
Sector | Health | Technology |
52-Week High | $168.62 | $901.60 |
52-Week Low | $121.80 | $252.76 |
Typical Hold Time | 82 Days | 18 Days |
Enterprise Value | $315.32B | $19.39B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
SiTime Corp (SITM) trades at $665.16, down 6.46% today but maintains strong analyst support with 100% buy ratings and a $751.43 consensus price target. The stock shows bullish technical signals with support at $659 and resistance at $678, while recent quarterly earnings consistently beat expectations. Revenue growth accelerated to 126.5% year-over-year in Q2 2026, driven by AI infrastructure demand and the Renesas acquisition, though current valuation metrics remain elevated with P/S at 37.99.
SITM presents significant growth potential as a precision timing specialist benefiting from AI data center expansion, with projected revenue growth and margin expansion. However, risks include high valuation multiples, insider selling activity, and dependence on sustained AI infrastructure spending. The stock's current pullback may offer entry opportunity given strong fundamental momentum and unanimous Wall Street optimism.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →